Atopic Dermatitis

The IL-13 inhibitor, recently FDA-approved for moderate to severe AD, reached all primary endpoints in the study focusing on patients with skin of color.

Ebglyss is now approved for children and adults aged 12 years and older.

Hurricane flooding results in a surge of mold, mildew, and allergens, which can trigger or exacerbate AD symptoms.

The TARGET-DERM registry longitudinal study highlighted the continued trend of the failure to escalate atopic dermatitis treatments when patients do not meet their therapeutic targets.

This week’s collection of the latest dermatologic studies includes the implementation of an action plan for patients with atopic dermatitis, early childhood eczema and the risk of allergic multicomorbidities, and more.

A recent study revealed a spectrum of photosensitivity in AD, with varying symptoms and sensitivities.

By setting higher treatment goals, the AHEAD recommendations emphasize the importance of achieving optimal targets for both skin clearance and itch relief in atopic dermatitis.

Results from the study highlight that the therapy improves AD symptoms over time, with 71.9% of participants achieving substantial improvement.

The AHEAD recommendations focus on achieving disease control in atopic dermatitis by allowing patients to identify key symptoms and clinicians to select matching outcomes to guide therapy, aiming for a higher standard of care.

The study found that after 4 weeks of using the action plan, AD severity decreased markedly, with many patients achieving mild AD status.

The study found 95.8% of ocular AEs occurred in AD patients, while SA patients reported only 4.2% of these events.

Patients with AD and psoriasis both report diminished levels of happiness compared to the general population.

Jayme Heim, MSN, FNP-BC, explores strategies for optimizing the mechanisms of action of topical JAK inhibitors in treating a 36-year-old male patient with a history of atopic dermatitis, highlighting the potential benefits and considerations of this therapeutic approach.

An atopic dermatitis expert presents a case study of a 36-year-old male with a history of atopic dermatitis, emphasizing the limitations of over-the-counter corticosteroids and discussing more effective treatment options.

A key opinion leader in the field of dermatology examines treatment strategies and medication sequencing for atopic and hand dermatitis in a 20-year-old female patient, focusing on clinical considerations and optimal management approaches.

Jayme Heim, MSN, FNP-BC, presents a case study on managing atopic dermatitis in a 20-year-old female patient.

Researchers stated the integration of wearable sensors with AI could potentially revolutionize care for patients with atopic dermatitis.

Learn more about the OX40-OX40L pathway and 2 drugs heading toward phase 3 trials.

Researchers suggested that itch control is key in reducing disease burden and improving life quality for patients with psoriasis and atopic dermatitis.

John Browning, MD, FAAD, FAAP, MBA, discusses the new online platform that allows young patients to share their skin journey with others.

Kindred spoke with Dermatology Times to discuss AbbVie's recent Science of Skin event and improving access to equitable dermatological care.

Jared Gollob, MD, shares highlights of Kymera Therapeutics' recent JID publication.

Kristine Kucera, MPAS, PA-C, DHS, discusses her patient's challenging atopic dermatitis that was eventually cleared with upadacitinib.

Researchers said they hope this consensus guides prescribing decisions among clinicians and encourages development of a standard approach.

The 15-piece questionnaire is designed to be quick and easy to use during consultations, with particular benefits across numerous specialties.

A growing body of research is dedicated to understanding how various climatic elements impact AD.